quinazolines has been researched along with Myelomonocytic Leukemia, Chronic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akashi, K; Harada, T; Ijichi, K; Iwama, E; Nakanishi, Y; Obara, T; Ogata, H; Okamoto, I; Yoshimoto, G | 1 |
| Abe, K; Giese, NA; Hollenbach, SJ; Hutchaleelaha, A; Lambing, JL; Pandey, A; Rose, JW; Scarborough, RM; Seroogy, JM; Volkots, DL; Yu, JC | 1 |
2 other study(ies) available for quinazolines and Myelomonocytic Leukemia, Chronic
| Article | Year |
|---|---|
Chronic myelomonocytic leukemia blast crisis in a patient with advanced non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
Topics: Afatinib; Agranulocytosis; Blast Crisis; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Genes, erbB-1; Humans; Leukemia, Myelomonocytic, Chronic; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.
Topics: Administration, Oral; Animals; Biological Availability; Dogs; Enzyme Inhibitors; Female; fms-Like Tyrosine Kinase 3; Humans; In Vitro Techniques; Leukemia, Experimental; Leukemia, Myelomonocytic, Chronic; Macaca fascicularis; Male; Mice; Mice, Nude; Microsomes, Liver; Mutation; Phosphorylation; Piperazines; Plasma; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; Quinazolines; Rats; Rats, Inbred Lew; Receptor Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor beta; Receptors, Platelet-Derived Growth Factor; Structure-Activity Relationship; Tumor Cells, Cultured | 2002 |